NanoViricides Provides Update on COVID-19 Coronavirus Drug Development Program at Benzinga Healthcare Small Cap Conference

0

An updated company presentation that encompasses Dr. Diwan’s presentation at the Benzinga conference will be available shortly on the company’s website on its home page (www.nanoviricides.com).

Highlights of the presentation:

  • TWO drug candidates, NV-CoV-2 and NV-CoV-2-R in development for entry into clinical trials
  • Both have broad-spectrum activities against many coronaviruses
    • Both should therefore continue to work against variants
    • Although SARS-CoV-2 continues to evolve with increasing resistance to existing drugs and antibodies
    • The variants could not therefore escape our drugs, in particular NV-CoV-2-R
  • New mechanism of action, unlike existing drugs
  • NV-CoV-2-R is the only drug in development with a dual mode of action
    • Prevent the virus from attacking cells in the first place, and
    • Inhibit virus replication inside cells, simultaneously
  • NV-CoV-2-R is the only drug in development that blocks the entire life cycle of the virus
    • The NV-CoV-2 component neutralizes the virus outside the cells blocking the cycle of reinfection
    • The Remdesivir component blocks the replication cycle inside cells
    • It is very difficult for the virus to escape from the medicine
  • Animal model studies have indicated that NV-CoV-2 and NV-CoV-2-R are significantly superior to Remdesivir in controlling fatal pulmonary coronavirus infection.
    • Lifespan extension on infected untreated animals:
      • Remdesivir: 2.5 days (only 50% increase)
      • NV-CoV-2: 14 days (180% increase)
      • NV-CoV-2-R: 16 days (220% increase).
  • NV-CoV-2 and NV-CoV-2-R are both extremely safe
    • NV-CoV-2 well tolerated at> 3.3 g / kg body weight in rats by IV infusion
    • NV-CoV-2-R well tolerated at> 1.8 g / kg body weight in rats by IV infusion
    • Anticipate a substantial therapeutic margin of safety in clinical studies
  • Required GLP safety / toxicology studies of NV-CoV-2 completed
    • No Adverse Effects on Respiratory or Neurological Function in a BPL Neuro-Pulmonary Study Model in Rats
    • No adverse effects on cardiovascular function in a BPL study in the cynomolgus monkey model (non-human primate)

“It is important to note that NV-CoV-2 can be administered orally and has been shown to be effective when administered orally in an animal model,” added Dr. Diwan. medical need which remains unmet, even with the current developments of the most discussed drugs “.

About the Benzinga Healthcare Small Cap conference

Benzinga Healthcare Small Cap Conference bridges the gap between small cap companies, investors and traders. Learn about small cap investing with clearly defined educational modules, take a look at an organized group of small cap investing opportunities, and connect with the small cap healthcare audience in an intimate virtual setting. We invite investors and all interested parties to explore investment opportunities in the small-cap healthcare sector through two days of networking, trading and discovery. For more information and / or to register for the conference, please visit: https://www.benzinga.com/events/small-cap/healthcare/.

About nanoviricides

NanoViricides, Inc. (the “Company”) (http://www.nanoviricides.com) is a developmental company that creates special-purpose nanomaterials for antiviral therapy. The Company’s new class of nanoviricide® drug candidates are designed to specifically attack and dismantle enveloped viral particles. We are developing clinical candidates for the treatment of COVID-19 disease caused by the SARS-CoV-2 coronavirus. Our other lead drug candidate is NV-HHV-101 with its first indication as a topical skin cream for the treatment of shingles rash. In addition, the Company has several antiviral programs at various preclinical stages.

The Company is currently working on tasks to complete an IND application for its COVID-19 drug candidates. The Company cannot predict an exact date for the filing of an IND for this drug due to its dependence on several collaborators and external consultants. The Company is currently seeking two distinct drug candidates for the treatment of patients with COVID-19. NV-CoV-2 is our nanoviricidal drug candidate that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate consisting of NV-CoV-2 in which remdesivir is encapsulated. The Company believes that since remdesivir is already approved by the US FDA, our encapsulating drug candidate remdesivir is likely to be an approved drug, if the safety is comparable. Remdesivir is developed by Gilead. The Company has independently developed its own NV-CoV-2 and NV-CoV-2-R drug candidates.

The Company intends to re-engage in an IND application with the US FDA for the drug candidate NV-HHV-101 for the treatment of shingles once its COVID-19 project goes into clinical trials, according to availability of resources. The NV-HHV-101 program has been slowed down due to the effects of recent COVID-19 restrictions and the re-prioritization of COVID-19 drug development work.

The Company is also developing drugs against a number of viral diseases, including oral and genital herpes, viral diseases of the eye, including EKC and herpetic keratitis, H1N1 swine flu, H5N1 avian flu, seasonal flu, HIV, hepatitis C, rabies, dengue, and Ebola, among others. The NanoViricides platform technology and programs are based on TheraCour’s TheraCour® nanomedicine technology, which TheraCour licenses to AllExcel. NanoViricides holds an exclusive worldwide perpetual license on this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: human coronavirus infections, human immunodeficiency virus (HIV / AIDS), virus of the hepatitis B (HBV), hepatitis C virus (HCV), rabies, herpes simplex virus (HSV-1 and HSV-2), varicella zoster virus (VZV), influenza virus and Asian avian influenza , dengue virus, Japanese encephalitis virus, West Nile virus and Ebola / Marburg virus. The Company’s technology is based on extensive, exclusive and sublicensable field licenses for drugs developed in these areas by TheraCour Pharma, Inc. The Company’s business model is based on the licensing technology of TheraCour Pharma Inc. for specific vertical applications of specific viruses, as established when it was founded in 2005.

As usual, the Company must point out the risk factor that the path to the development of a drug typical of any pharmaceutical product is extremely long and requires substantial capital. As with any company drug development effort, there can be no assurance at this time that any of the Company’s drug candidates will demonstrate sufficient efficacy and safety for human clinical development. In addition, there is no guarantee at this time that positive results against the coronavirus in our laboratory will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectations regarding future events. Actual events could differ materially and substantially from those anticipated herein and depend on a number of factors. Certain statements contained in this press release and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements, as they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the control of the Company and which could, and probably will, a material impact on actual results, activity levels, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons why actual results could differ materially from those anticipated in such forward-looking statements, even if new information becomes available in the future. Significant factors that could cause actual results to differ materially from the Company’s expectations include, without limitation, factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the Company. from time to time with the United States. Securities and Exchange Commission and other regulatory authorities. While it is not possible to predict or identify all of these factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; the successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we seek; the successful commercialization of our product candidates; and market acceptance of our products.

The FDA refers to the United States Food and Drug Administration. IND’s request refers to the “new investigative drug” request. cGMP refers to current good manufacturing practices. CMC refers to “Chemistry, Manufacturing and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency (EMA) committee responsible for medicines for human use.

SOURCE NanoViricides, Inc.

Related links

http://www.nanoviricides.com


Source link

Leave A Reply

Your email address will not be published.